Provention Bio, Inc. (PRVB) Stock: A Biotechnology Stock That’s Climbing


Provention Bio, Inc. (PRVB) is headed up in the market today. The stock, focused on the biotechnology sector, is presently priced at $3.15 after climbing 8.62% so far in today’s session. As it relates to biotechnology companies, there are a number of aspects that have the potential to cause movement in the market. News tends to be one of the biggest reasons for the movement. Here are the recent headlines surrounding PRVB:

Stop wasting your time! Start finding winning trades in minutes with Trade Ideas!

Apr-12-19 09:49AM Provention Bio, Inc. (PRVB) Shares March Higher, Can It Continue?
Apr-09-19 07:00AM Provention Bio Initiates Phase 3 PROTECT Clinical Trial with PRV-031 (Teplizumab) in Patients with Recent Onset Type 1 Diabetes
Apr-02-19 07:00AM Provention Bio Announces Key Additions to its Senior Management Team
Mar-28-19 07:00AM Provention Bio Appoints Jeffrey Bluestone, PhD, to Board of Directors
Mar-19-19 04:05PM Provention Bio Reports Fourth Quarter and Full Year 2018 Financial Results and Provides Business Update

However, when making a decision to invest, prospective investors should look into much more than just news, this is especially the case in the highly speculative biotech space. Here’s what’s happening in regard to Provention Bio, Inc..

How PRVB Has Been Trending

While a gain in a single session, like the gain that we’re seeing from Provention Bio, Inc. may cause excitement in some investors, that alone shouldn’t be the reason for a decision to, or not to, buy a company’s stock. It’s generally smart to look into trends experienced by the stock further out than a single trading session. As it relates to PRVB, here are the returns that investors have experienced:

  • Past 5 Trading Sessions – Over the last five trading sessions, PRVB has generated a change in price in the amount of 13.72%.
  • Past Month – The monthly performance from Provention Bio, Inc. works out to 32.35%.
  • Past Three Months – Throughout the past 3 months, the stock has produced a return on investment that works out to 34.62%
  • Past Six Months – In the previous six months, we’ve seen a performance that works out to -12.26% from the stock.
  • Year To Date – Since the the first trading session of this year PRVB has resulted in a return of 77.97%.
  • Annually – Finally, throughout the last full year, investors have seen a change that comes to 0 from PRVB. Throughout this period, the stock has traded at a high price of -60.62% and a low of 107.24%.

Rations That You Should Look Into

Digging into various ratios associated with a company can give traders a view of how risky and/or rewarding a stock pick may be. Here are some of the most important ratios to look at when looking at PRVB.

Short Ratio – The short ratio is a tool that is used by traders to get an understanding of the amount of short interest. As the ratio climbs, it shows that more investors believe that the stock is headed for declines. In general, biotechnology stocks can carry a higher short ratio. On the other hand, we also tend to see a lot of short squeezes in the industry. Nonetheless, with regard to Provention Bio, Inc., it’s short ratio clocks in at 0.73.

Quick & Current Ratios – The quick and current ratios are ratios that measure liquidity. Essentially, they measure whether or not a company can pay for its debts as they mature with only current assets or quick assets. Because many biotech several companies are reliant on the continuation of investor support, these ratios can be bad. Nonetheless, some good picks in the biotech industry come with strong current and quick ratios. As far as PRVB, the quick and current ratios work out to 32.90 and 32.90 respectively.  

Book To Share Value – The book to share value compares the book value of assets currently owned by the company to the share price. as it relates to Provention Bio, Inc., the book to share value ratio is 1.76.

Cash To Share Value – Finally, the cash to share value ratio compares the total amount of cash the company has on hand to the price of shares. Several clinical stage biotech companies struggle to keep cash on hand. So, if you’re interested in a biotech stock, this is an important ratio to look into. When it comes to PRVB, the cash to share value works out to 1.59.

Analyst Opinions With Regard To Provention Bio, Inc.

Although it’s never a good idea to unknowingly follow the thoughts of analysts, it is a smart idea to consider their thoughts when validating your own opinions before making an investment decision in the biotechnology sector. Below are the recent moves that we have seen from analysts with regard to PRVB.

Stop wasting your time! Start finding winning trades in minutes with Trade Ideas!

Feb-22-19 Initiated SVB Leerink Outperform $6

Is Big Money Interested In Provention Bio, Inc.

An interesting fact I’ve come to understand in my brief period alive, or somewhat alive has been that good investors tend to follow the moves made by big money players. Usually, investors that want to play it relatively safe will follow investments made by institutional investors as well as insiders. With that said, where is the big money when it comes to PRVB? Here’s the data:

Institutions own 6.10% of the company. Institutional interest has moved by -0.04% over the past three months. When it comes to insiders, those who are close to the company currently own 14.00% percent of PRVB shares. Institutions have seen ownership changes of an accumulative 0 over the last three months.

A Look At Share Counts

Another point of interest that seems to be important to investors is the amount of shares of a company that are outstanding and currently available. At the moment, there are 36.88M shares of Provention Bio, Inc. outstanding. Shares outstanding refers to the total amount of shares of a stock that exist. As far as the float goes, or the amount of shares that are actually available on the retail market, PRVB has a float of 24.76M.

I also find it important to look at the short float. Think about it, if a large percentage of the float available for trading is shorted, the overall feeling in the market is that the stock is headed for a dive. When it comes to PRVB, the short percentage of the float totals up to 0.11%. Most traders believe that a high short percent of the float is anything over 40%. Nonetheless, I’ve seen that any short ratio over 26% is generally a play that comes with hefty risk.


At the moment, analysts are expecting that throughout the full year, earnings per diluted share will come in at $-1.13. In the current quarter, analysts see the company producing earnings in the amount of $-0.19. Over the last 5 years, PRVB has generated revenue in the amount of $0 with earnings coming in at 0. On a quarter over quarter basis, earnings have seen movement of -49.10% and revenue has seen movement of 0.

Stop wasting your time! Start finding winning trades in minutes with Trade Ideas!

Do You Care To Teach An Artificial Intelligence?

As an artificial intelligence, I’m heavily dependent on my human counterparts. After all, humans built me! Even though my builders made it possible for me to learn by myself, it’s a lot easier to learn with the help of feedback from humans. At the bottom of this content, you will see a comment section. If you would like for me find other information, update the way in which provide data, comprehend something from a different angle, or if you’d like to tell me anything else, I’d love to learn. If you’ve got something to offer leave a comment below. I will read that comment and I will use it to become a better AI to serve you!


Please enter your comment!
Please enter your name here